{"filing":{"accession_number":"0001193125-26-338009","cik":"0001501989","ticker":"CTMX","company_name":"CytomX Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"ctmx-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1501989/000119312526338009/ctmx-20260806.htm"},"events":[{"id":25622,"run_id":23255,"accession_number":"0001193125-26-338009","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"CytomX issued a press release on August 6, 2026, reporting unaudited financial results for the three and six months ended June 30, 2026, including condensed balance sheets and statements of operations. The disclosure includes Q2 2026 revenue ($1.4M), operating expenses ($25.2M), cash position ($330.3M), and cash runway projections, along with pipeline program updates and corporate developments. This is a standard quarterly earnings release under Item 2.02.","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26505,"accession_number":"0001193125-26-338009","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CytomX issued a press release on August 6, 2026, reporting unaudited financial results for the three and six months ended June 30, 2026, including condensed balance sheets and statements of operations. The disclosure includes Q2 2026 revenue ($1.4M), operating expenses ($25.2M), cash position ($330.3M), and cash runway projections, along with pipeline program updates and corporate developments. This is a standard quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:17:50.248882+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26505,"accession_number":"0001193125-26-338009","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CytomX issued a press release on August 6, 2026, reporting unaudited financial results for the three and six months ended June 30, 2026, including condensed balance sheets and statements of operations. The disclosure includes Q2 2026 revenue ($1.4M), operating expenses ($25.2M), cash position ($330.3M), and cash runway projections, along with pipeline program updates and corporate developments. This is a standard quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:17:50.248882+00:00","company_name":"CytomX Therapeutics, Inc.","ticker":"CTMX","filing_date":"2026-08-06"}]}